Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Eli Lilly to Continue Schizophrenia Drug Program In Spite Of “Inconclusive” Study Results

By Pharmaceutical Processing | March 30, 2009

INDIANAPOLIS (AP) — Eli Lilly & Co. said Sunday it will continue developing a potential schizophrenia treatment and considered recent midstage study results “inconclusive” after the drug candidate was no more effective than placebo. The company said it considers the midstage, or Phase II, study results inconclusive because of the unusually high response rate from patients taking placebo. It saw more than double the response in those patients than is historically seen in such studies. The drug developer said “inconclusive” study results are common in the field of neuroscience. The results were presented at the 12th International Congress on Schizophrenia Research in San Diego. In all, 669 patients enrolled and 393 completed the study. None of the four doses of mGlu2/3 were more effective than placebo and three patients taking the drug suffered from convulsions. Other than the convulsions, the company said the drug was well-tolerated. Eli Lilly also said the already approved anti-psychotic Zyprexa was no more effective than placebo when given in 15-milligram doses, once-daily. Zyprexa has previously proved more effective than placebo. The company plans to start another midstage clinical trial on mGlu2/3. Leerink Swann analyst Seamus Fernandez called the results a “serious blow” to Eli Lilly’s pipeline. “We believe any additional studies (with the drug candidate) should be viewed as exploring the mGlu2/3 mechanism, but the agent should not move forward into Phase III studies due to safety concerns,” he said, in a note to investors. Fernandez said consultants familiar with the drug’s development have said it now demonstrated either convulsions or seizures in two species, including humans.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE